On Friday, Metsera earned a positive adjustment to its Relative Strength (RS) Rating, from 79 to 82.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating measures share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.
Metsera is not currently offering a proper buying opportunity. See if the stock goes on to form a base that could kick off a new climb.
Metsera posted 0% earnings growth last quarter, while sales growth came in at 0%.
Metsera earns the No. 325 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
